Stock Market Reviews

SEPN (Septerna, Inc.) News

Get the latest news, insights, and market updates on SEPN (Septerna, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
  SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upco
  Nov 10, 2025 - $SEPN
• Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
  Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +13.79% and -4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $SEPN
• Septerna to Participate in Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside chat on Monday, November 10, 2025, at 4:00 p.m. ET TD Cowen Immunology & Inflammation SummitFireside chat on Wednesday, N
  Nov 3, 2025 - $SEPN
• Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength?
  Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Oct 31, 2025 - $SEPN
• Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
  Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Oct 22, 2025 - $SEPN
• Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
  Septerna, Inc. (SEPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Oct 9, 2025 - $SEPN
• Septerna (SEPN): Evaluating Valuation Following Dr. Keith Gottesdiener’s Board Appointment
  Septerna (SEPN) just appointed Dr. Keith Gottesdiener, a biotech leader with decades of R&D experience, to its board. His background in successful drug development is already sparking interest in Septerna’s strategic direction. See our latest analysis for Septerna. Shares of Septerna have surged in recent weeks, posting a robust 53% 1-month share price return and nearly doubling over the past quarter. Momentum appears to be building as fresh leadership and R&D expertise rekindle optimism...
  Oct 9, 2025 - $SEPN
• Are Options Traders Betting on a Big Move in Septerna Stock?
  Investors need to pay close attention to SEPN stock based on the movements in the options market lately.
  Oct 3, 2025 - $SEPN
• Septerna Up 12%, Insider Buyers Are Up 219%
  Septerna, Inc. ( NASDAQ:SEPN ) insiders who bought shares over the past year were rewarded handsomely last week. The...
  Oct 2, 2025 - $SEPN
• LEXX: Biodistribution Study Results
  By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this
  Oct 2, 2025 - $SEPN